Gilead Sciences submitted a new drug application for redsiwe to the FDA for the treatment of COVID-19.

Redsivir is an experimental nucleotide analogobial with broad-spectrum antiviral activity in both in vitro and in vivo animal models to fight against a variety of emerging viral pathogens.
more ongoing International Phase 3 clinical trials are evaluating the safety and effectiveness of its use in treating new coronavirus infections that cause COVID-19 in different patient populations, formulations, and in combination with other therapies.
has been approved by regulators around the world, including the European Union and Japan.
application was supported by two randomized, open-label, multi-center Phase 3 clinical trials conducted by Gilead Sciences and randomized, placebo-controlled Phase 3 studies conducted by the National Institute of Allergy and Infectious Diseases (NIAID).
these studies have shown that Redsyve treatment leads to faster recovery times for patients than placebos, and that a five- or 10-day course of treatment can provide similar clinical improvements.
Redsyve molecular structure (Photo: Hbf878 / CC0) "Since the pandemic, Gilead Sciences has worked with the highest urgency to determine the effectiveness and safety of Redsyve, and we now have a strong data set to support "Today's application is an important milestone and we will continue to work with healthcare organizations around the world to address the treatment needs of COVID-19 patients," said Dr. Merdad Parsey, Chief Medical Officer of Gilead Sciences.
" References: s1. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for The Treatment of COVID-19. Retrieved August 10, 2020, from.